Product Details

Nivolumab is a fully human monoclonal antibody (IgG4) that specifically targets the programmed cell death-1 (PD-1) receptor. As a biosimilar to the FDA-approved therapeutic nivolumab, it is designed to block the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby enhancing T-cell activation and restoring immune responses against cancer cells. Nivolumab binds to the PD-1 receptor on T cells, preventing its engagement with PD-L1 and PD-L2. This blockade inhibits immune checkpoint signaling, allowing T cells to remain active and effectively attack tumor cells. By overcoming immune suppression, nivolumab plays a critical role in cancer immunotherapy research.